

1 **Full title:** Long-term efficacy of orthokeratology contact lens wear in controlling  
2 the progression of childhood myopia

3

4 **Authors:** Jacinto Santodomingo-Rubido, PhD, MSc, OD, MCOptom, FBCLA,  
5 FAAO \*; César Villa-Collar PhD, MSc, OD, FAAO <sup>§¶</sup>; Bernard Gilmartin PhD,  
6 BSc, FCOptom <sup>δ</sup>; Ramón Gutiérrez-Ortega, PhD, MD<sup>§</sup>; Keiji Sugimoto, BSc.

7

8 **Institutional affiliations:**

9 \*Menicon Co., Ltd, Nagoya, Japan

10 <sup>§</sup>Clínica Oftalmológica Novovision, Madrid, Spain

11 <sup>¶</sup>Universidad Europea de Madrid, Madrid, Spain

12 <sup>δ</sup>School of Life and Health Sciences, Aston University, Birmingham, UK

13

14 **Corresponding author:** Jacinto Santodomingo-Rubido

15

16 **Tel:** +34 610 832 234

17

18 **Email:** j.santodomingo@icloud.com

19

20 **Number of tables:** 4

21

22 **Number of figures:** 6

23

24 **Manuscript word count (excluding references):** 4,032

25

26 **Date of submission:** May 20<sup>th</sup>, 2016

27 **Date of resubmission:** July 22<sup>nd</sup>, 2017

28

29 **ABSTRACT**

30

31 **PURPOSE:** The primary outcome of this study is to compare axial length growth of white  
32 European myopic children wearing orthokeratology contact lenses (OK) to a control group (CT)  
33 over a 7-year period.

34

35 **METHODS:** Subjects 6-12 years of age with myopia -0.75 to -4.00DS and astigmatism  $\leq 1.00$ DC  
36 were prospectively allocated OK or distance single-vision spectacles (SV) correction.  
37 Measurements of axial length (Zeiss *IOLMaster*), corneal topography and cycloplegic refraction  
38 were taken at 6-month intervals over a 2-year period. Subjects were invited to return to the clinic  
39 approximately 5 years later (i.e. 7 years after the beginning of the study) for assessment of their  
40 ocular refractive and biometric components. The CT consisted of 4 SV and 12 subjects who  
41 switched from SV to soft contact lens wear after the initial 2-years of SV lens wear. Changes in  
42 axial length relative to baseline over a 7-year period were compared between groups.

43

44 **RESULTS:** Fourteen and 16 subjects from the OK and CT groups, respectively were examined  
45  $6.7 \pm 0.5$  years after the beginning of the study. Statistically significant changes in axial length  
46 were found over time and between groups (both  $p < 0.001$ ), but not for the time\*group interaction  
47 ( $p = 0.125$ ). The change in axial length for the OK group was 22% ( $p = 0.328$ ), 42% ( $p = 0.007$ ),  
48 40% ( $p = 0.020$ ), 41% ( $p = 0.013$ ) and 33% ( $p = 0.062$ ) lower than the CT group following 6, 12, 18,  
49 24 and 84 months of lens wear, respectively.

50

51 **CONCLUSION:** A trend towards a reduction in the rate of axial elongation of the order of 33%  
52 was found in the OK group in comparison to the CT group following 7-years of lens wear.

53

54

55

56 **Key words:** myopia control, orthokeratology, axial length, myopia progression, long-term  
57 efficacy

58

59

60

61

62

63

64

## 65 INTRODUCTION

66 Globally, uncorrected refractive errors represent the second major cause of  
67 vision loss<sup>1</sup> of which myopia is the most common and distinctive in that its  
68 prevalence has increased substantially in recent decades. To date, it has been  
69 estimated that myopia currently affects approximately 30% of the world's  
70 population,<sup>2, 3</sup> although a significant increase to affect around 50% of the  
71 world's population by 2050 has been forecast.<sup>2</sup> The prevalence of myopia in  
72 young adolescents is also increasing and has approached around 25% and up  
73 to 98% in industrialized societies of the West and East Asia, respectively.<sup>3</sup> Of  
74 particular concern is that relatively low degrees of myopia may be associated  
75 with increased risk of ocular complications, such as vitreous and chorioretinal  
76 detachment, macular degeneration, and glaucoma all of which can increase the  
77 risk of vision loss.<sup>4-7</sup> Furthermore, myopia incurs substantial expenditure such  
78 that in the USA, the annual cost for eye examinations and corrections by  
79 spectacles and contact lenses has been estimated to be between \$2 and \$5  
80 billion.<sup>8, 9</sup> Therefore, finding effective therapies to slow the progression of  
81 myopia could potentially benefit millions of individuals and save on substantial  
82 healthcare expenditure worldwide.

83

84 Several optical treatment options have been used in the past with limited  
85 success to eliminate or, at least, reduce myopia progression in children.<sup>10-12</sup> Of  
86 these, orthokeratology (OK) contact lens wear appears to be one of the most  
87 effective as it has consistently been shown to reduce the axial elongation of the  
88 eye by 30 to 50% in comparison with conventional single-vision spectacle (SV)  
89 and soft contact lens (SCL).<sup>13-18</sup> Most previous studies have demonstrated  
90 reduced rates in axial elongation over 2 years of OK lens wear. A recent meta-  
91 analysis study reported that the pooled reduction in axial elongation declined  
92 with time, with 55, 51, 51, and 41% obtained after 6, 12, 18, and 24 months of  
93 OK lens wear, respectively.<sup>19</sup> However, little is known about the efficacy of OK  
94 lens wear in reducing the rate of axial elongation for longer periods of lens  
95 wear. Two retrospective studies have shed some light on the latter.<sup>20, 21</sup> Kwok-  
96 Hei Mok and Sin-Ting Chung compared changes in myopia over a 7-year period  
97 between 34 children with a mean age at baseline of 9 years wearing OK and 36  
98 children with a mean age at baseline of 10 years wearing SV.<sup>20</sup> Determination

99 of the final refractive error of the OK lens wearing subjects was conducted by  
100 the washout period method, whereby subjects were refracted after not wearing  
101 the lenses for a period of time until the flatter corneal meridian reverted to its  
102 pre-OK levels.<sup>20</sup> It took a mean ( $\pm$  standard deviation) of  $25.5\pm 1.0$  (range 22–  
103 29) days for the central flat corneal curvature to return to pre-OK levels.  
104 Average myopic progression for the OK group ( $-0.37\pm 0.49$ D) was significantly  
105 lower than that found for the SV group ( $-2.06\pm 0.81$ D) following 7-years of lens  
106 wear.<sup>20</sup> Downie and Lowe compared the progression rate of manifest refractive  
107 prescription in myopic children under the age of 16 years between 26 OK lens  
108 wearers and 30 age- and refraction-matched SV wearers in 2 yearly intervals  
109 over a period up to 8 years.<sup>21</sup> The study found that OK wearers showed a  
110 significantly more stable myopic refractive prescription than SV over all of the 2-  
111 year treatment intervals, indicating that OK can reduce the rate of progression  
112 of childhood myopia over the long term.<sup>21</sup> Furthermore, a subpopulation of OK  
113 lens wearers (64%) demonstrated an apparent total arrest of manifest myopic  
114 refractive change.<sup>21</sup> Although the above two studies have provided preliminary  
115 evidence for the long-term efficacy of OK contact lens wear in reducing the  
116 progression of myopia their limitations are retrospective study designs, non-  
117 randomization of subjects to study groups and the use of non-cycloplegic  
118 refractions as primary outcome measures. Furthermore, neither of the studies  
119 measured axial length, the key structural correlate of myopic progression in OK-  
120 treated eyes.<sup>22</sup> Hiraoka et al. compared changes in axial length between 22 OK  
121 and 21 SV Japanese lens wearers with a mean age at baseline of 10 years  
122 over a period of 5 years.<sup>23</sup> The study found statistically significant reductions in  
123 the annual increases in axial length in the OK group compared with the SV  
124 group for the first, second, and third years, but not for the fourth and fifth  
125 years.<sup>23</sup>

126

127 We have previously reported the results of the Myopia Control with  
128 Orthokeratology contact lens in Spain (MCOS) study which evaluated  
129 differences in growth of axial length over a 2-year period in white European  
130 children with myopia wearing OK and SV.<sup>17</sup> We found a statistically significant  
131 difference in axial length elongation relative to baseline between the OK  
132 ( $0.47\pm 0.18$ mm) and SV ( $0.69\pm 0.32$ mm) groups ( $p=0.005$ ).<sup>17</sup> Approximately 5

133 years after completion of the MCOS study, subjects were contacted by  
134 telephone and invited to return to the clinic for evaluation of their ocular  
135 refractive and biometric parameters. The purpose of this study is to compare, as  
136 the primary outcome measure, differences in growth of axial length over a 7-  
137 year period between white European myopic children wearing OK and a control  
138 group (CT) wearing SV or SCL. Additionally, refractive and biometric changes in  
139 subjects who switched corrections were also evaluated.

140

141

142

143

## 144 **METHODS**

145 This study was part of a larger study designed to assess different aspects of OK  
146 lens wear specifically prescribed for the control of myopia progression in  
147 children.<sup>17, 24-27</sup> The methods employed in MCOS have been described in detail  
148 elsewhere.<sup>17, 24</sup> In brief, normal, healthy white European subjects 6 to 12 years  
149 of age with moderate levels of mean spherical myopia (-0.75 to -4.00D) and  
150 astigmatism ( $\leq 1.00$ D) and free of systemic or ocular disease were fitted with  
151 Menicon Z Night contact lenses for overnight use (Menicon Co., Ltd, Nagoya,  
152 Japan). An OK fit was considered to be successful if the subject showed a  
153 CCLRU score regarding anterior eye segment signs  $\leq 1$  unit, a “bull’s eye”  
154 corneal topography pattern and monocular and binocular visual acuities within  
155  $\pm 1$  line of the best-correct spectacle visual acuity. All subjects underwent ocular  
156 examinations including slit-lamp examination, manifest refraction, and corneal  
157 topography at baseline and at 6-month intervals over a 2-year period. Follow-up  
158 visits were scheduled to fall within 2 hours of awakening in order to measure  
159 subjective refraction and visual acuity without the lens on the eye. A decrease  
160 in one line of visual acuity accompanied by a change in subjective refraction at  
161 any of the follow-up visits was considered clinically significant and was  
162 remedied by supplying new contact lenses. Approximately 5 years after  
163 completion of the MCOS study, subjects were contacted by telephone and  
164 invited to return to the clinic for evaluation of their ocular refractive and  
165 biometric parameters. The study was conducted in accordance with the Tenets  
166 of the Declaration of Helsinki and approved by the Institutional Ethical  
167 Committee Review Board of Novovision Ophthalmology Clinic (Madrid, Spain).  
168 Full informed consent and child assent was obtained in writing from the  
169 parents/guardians prior to the start of all experimental work and data collection.  
170 Patient participation in the study could be discontinued at the examiner’s  
171 discretion should significant symptoms or slit-lamp findings occur. Subjects  
172 were instructed they could withdraw from the study at any time.

173

174 Cycloplegic auto-refraction was performed following the instillation of three  
175 drops of cyclopentolate HCl 1% separated 10 min apart in each of the subjects’  
176 eyes using a multidose bottle (Alcon Cusí, Masnou, Barcelona, Spain). Ten  
177 minutes after the instillation of the third drop, three auto-refraction

178 measurements were taken and a mean obtained (Topcon RM 8000B, CA,  
179 USA).

180

181 Measurements of axial length were taken with the Zeiss *IOLMaster* (Carl Zeiss  
182 Jena GmbH).<sup>28</sup> Three separate measurements of axial length were recorded  
183 and a mean obtained.

184

185 Corneal topography measurements were performed with the Wavelight Allegro  
186 Topolyzer (WaveLight Laser Technologies AG, Erlangen, Germany). The  
187 instrument incorporates a high resolution placido-ring corneal topographer  
188 which detects 22,000 elevated data points of measurement from 22 ring edges  
189 with a claimed accuracy and reproducibility of  $\pm 0.10D$  according to the  
190 manufacturer. The first measurement taken for each eye, which provided an  
191 optimum index value according to the manufacturer's recommendations, was  
192 used for the study. The measurement generates a simulated central  
193 keratometry reading and the rate of peripheral corneal flattening/steepening that  
194 occurs with displacement from the corneal apex; the latter indicates the degree  
195 to which an aspheric surface differs from the spherical form (i.e., the p value).  
196 The p value was calculated over a 7-mm chord in accord with the default setting  
197 of the instrument.

198

### 199 **Statistical analysis**

200 Differences in subjects' demographics and baseline data between groups were  
201 tested using unpaired sample t-tests for all variables, except for the male:female  
202 ratio which was tested using a chi-square test. Changes (from baseline) in  
203 refractive and biometric data over time and between groups (i.e. OK vs. CT)  
204 were tested using a general linear model (GLM) with repeated measures to test  
205 the statistical significance of differences in outcome variables (i.e. axial length,  
206 spherical and cylindrical refractive components, corneal power and corneal  
207 shape) for the between-subject factor of refractive correction (two levels: OK  
208 and CT) and for the within-subject factor of time (five levels: 6, 12, 18, 24 and  
209 84 months). The significance of the interaction between OK and CT with respect  
210 to time was then tested for all time intervals combined and then separately for  
211 each of the five time intervals following post hoc Bonferroni correction. GLM

212 with repeated measures was also used to test the effect of switching treatments  
213 from OK to SCL. Additionally, an unpaired sample t-test was used to test, for  
214 each time point, differences between the groups in refractive and biometric  
215 variables. Equality of variances and sphericity were tested using the Levene  
216 and Mauchly tests respectively to select appropriate p-values. Additionally,  
217 simple linear regressions between the change in axial length at 7-years relative  
218 to baseline and baseline age, mean spherical equivalent refractive error, axial  
219 length, mean central corneal power and corneal shape factor were calculated  
220 for the OK and CT groups separately. Differences between groups in the slopes  
221 of the regression lines were compared using an analysis of covariance. The  
222 strength of association between the different factors is summarized using linear  
223 regression equations,  $R^2$  squared values and p-values. Data are expressed as  
224 mean  $\pm$  1 standard error of the mean (SEM). Data from right eyes only were  
225 used for analysis. Statistical analyses were performed with *IBM SPSS Statistics*  
226 (IBM Corp., Ver. 22, NY, USA) and graphing with *SigmaPlot* (Systat software  
227 Inc, California, USA). The level of statistical significance was set at 5%.

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

## 243 **RESULTS**

244 At the inception of MCOS sixty-nine subjects were examined for eligibility: 8  
245 subjects were not eligible to participate and 31 and 30 children were  
246 prospectively allocated to OK and SV, respectively (Figure 1). Twenty-nine and  
247 24 subjects from the OK and SV groups, respectively, thus completed the initial  
248 2 years of the MCOS study. Seven subjects were subsequently lost to follow-  
249 up in each group and no further information was able to be collected from these  
250 subjects leading to a total of 39 subjects of the original cohort available for  
251 review at the 7-year visit. Of these, 14 and 4 remained in their original OK and  
252 SV lens wear categories, respectively. In addition, twelve of the 39 subjects  
253 switched to standard SCL wear after 2 years of SV lens wear which thus  
254 constituted a control group (CT) of 16 subjects (i.e. 4 SV + 12 SCL). Nine  
255 subjects switched lens wear category and the effect of which was assessed  
256 separately (see subheading below) (Figure 1).

257

### 258 **Long-terms effects in the OK and CT groups**

259 The OK and CT groups were followed for  $6.9\pm 0.1$  and  $6.5\pm 0.1$  years,  
260 respectively; this difference was statistically significant ( $p=0.001$ ). Subjects  
261 reported inserting and removing their OK lenses every night and morning,  
262 respectively. None of the subjects from the OK group reported cessation of lens  
263 wear for any significant periods of time over the entire 7-year period of OK lens  
264 wear. Furthermore, all subjects reported  $\leq 0.9$  uncorrected decimal visual  
265 acuities (equivalent to 0.05 logMAR or  $>20/25$ ) at the 7-year visit. The  
266 incidence, type and timeline of adverse events found over the initial 24 months  
267 of the study have been previously reported.<sup>25</sup> At the 84-month visit, all subjects  
268 underwent a thorough ophthalmic examination and no remarkable adverse  
269 events were found. Furthermore, none of the subjects reported any significant  
270 complications in the last 5 years of lens wear. The 12 subjects who switched to  
271 standard SCL wear after 2 years of SV lens wear and who became part of the  
272 CT group worn SCL for  $2.5\pm 0.4$  years prior to the 7-years visit. No statistically  
273 significant differences between the OK and CT groups were found in any of the  
274 baseline demographics and refractive and biometric data (Table 1).

275

276 Statistically significant changes were found in axial length both over time and  
277 between groups ( $p < 0.001$ ), but not for the time\*group interaction ( $p = 0.125$ )  
278 (Figure 2 and Table 2). Changes over time were statistically significant for all  
279 pairs of time points (all  $p \leq 0.001$ ) (Figure 2 and Table 2). In comparison to the  
280 CT group, the change in axial length for the OK group was 22% ( $p = 0.328$ ), 42%  
281 ( $p = 0.007$ ), 40% ( $p = 0.020$ ), 41% ( $p = 0.013$ ) and 33% ( $p = 0.062$ ) lower following 6,  
282 12, 18, 24 and 84 months of lens wear, respectively (Figure 2 and Table 2).

283

284 Statistically significant differences were also found in the spherical component  
285 of the refraction over time, between groups and for the time\*group interaction  
286 (all  $p < 0.001$ ) (Table 2). Statistically significant differences between time points  
287 were found between 6- and 12-, 18-, 24- and 84-months (all  $p < 0.01$ ); between  
288 12- and 84-months ( $p = 0.002$ ); between 18- and 24- and 84-months (both  
289  $p < 0.001$ ); and between 24- and 84-months ( $p < 0.001$ ) (Table 2). Statistically  
290 significant differences were found between groups at all the different time points  
291 ( $p < 0.001$ ) (Table 2). However, no statistically significant differences were found  
292 in the cylindrical component of the refraction over time, between groups or for  
293 the time\*group interaction ( $p > 0.05$ ) (Table 2).

294

295 Statistically significant differences were found in corneal power over time (both  
296  $p < 0.001$ ) and between groups (both  $p < 0.001$ ), but not for the time\*group  
297 interaction (both  $p > 0.05$ ) for both the flatter and steeper meridians (Table 2).  
298 Significant differences were found for pairs of time points between 6-, 12-, 18-,  
299 24- and 84-months for both meridians (all  $p \leq 0.02$ ) (Table 2). Significant  
300 differences were also found between groups in corneal power at all time points  
301 for both meridians (all  $p < 0.001$ ) (Table 2). However, no significant differences  
302 were found in the corneal shape (i.e. corneal p-value) over time, between  
303 groups or for the time\*group interaction (all  $p > 0.05$ ) (Table 2).

304

305 Univariate linear regression analysis revealed that the older the age at baseline  
306 the smaller the axial elongation at 7-years in both study groups, although the  
307 relationship was statistically significant for the CT ( $R^2 = 0.274$ ,  $p = 0.022$ ), but not  
308 for the OK group ( $R^2 = 0.142$ ,  $p = 0.101$ ). The effect of baseline age on axial  
309 elongation was, however, similar between groups ( $p = 0.208$ ) (Figure 3 and

310 Table 3). Greater corneal powers at baseline were associated with smaller  
311 increases in axial length in the OK group ( $R^2=0.290$ ,  $p=0.027$ ), but no significant  
312 relationship was found for the CT group ( $R^2=0.000$ ,  $p=0.817$ ) (Figure 4 and  
313 Table 3). Furthermore, statistically significant differences were found between  
314 groups in the slopes of the regression lines ( $p=0.044$ ) (Figure 4 and Table 3).  
315 No significant relationships were found between the change in axial length at 7-  
316 years in comparison to baseline and baseline mean spherical equivalent  
317 refractive error, axial length and corneal shape for either the OK or CT groups  
318 (Table 3). In addition, no statistically significant differences were found between  
319 groups in the slopes of the regression lines for either spherical equivalent  
320 refractive error, axial length or corneal shape (all  $p>0.05$ ) (Table 3).

321

### 322 **The effect of switching treatments**

323 Following 2 years of OK lens wear, eight subjects (4 male and 4 female)  
324 switched from OK to SCL 1.7 $\pm$ 0.5 years (range 0.2 to 3.9 years) thereafter and  
325 wore SCL for the last 3.3 $\pm$ 0.5 years (range 1.3 to 5.3 years). A trend was found  
326 for increased time of SCL wear to be associated with shorter increases in axial  
327 length (Figure 5). The reasons for switching from OK to SCL were (number of  
328 subjects): expensive treatment (4), recurrent punctate keratitis (2) and concerns  
329 regarding regression (1) and efficacy (1). These subjects had mean ages of  
330 9.3 $\pm$ 0.4, 11.4 $\pm$ 0.4 and 16.4 $\pm$ 0.5 at baseline, following 2 years of OK lens wear  
331 and at the 7-years study visit, respectively. On average, axial length increased  
332 by 0.57 $\pm$ 0.06mm during the initial 2 years of OK lens wear and by 0.80 $\pm$ 0.16mm  
333 on the subsequent 5 years (Table 4), although there was large between-subject  
334 variability (Figure 6). As expected, the increase in axial length following  
335 cessation of OK lens wear was associated with an increase in myopia, a  
336 steepening of corneal curvature and a more prolate corneal shape (Table 3). In  
337 comparison to the CT group (Table 2), these subjects experienced mean  
338 reductions in the rate of axial elongation of 47%, 30%, 22% and 19% following  
339 6, 12, 18 and 24 months of OK lens wear, respectively (Tables 2 and 4).  
340 However, when these subjects switched from OK to SCL the rate of axial  
341 elongation observed at 84 months in comparison to the CT group was -1%,  
342 indicating the effect of OK lens wear in reducing the rate of axial elongation is  
343 negligible with discontinuation of lens wear (Tables 2 and 4). One male subject

344 switched from SV to OK lens wear immediately after the initial 2 years of SV  
345 lens wear and wore OK lenses for the following 5 years. The reason for  
346 changing to OK was to reduce the rate of myopia progression. In this subject,  
347 axial length increased by 0.81mm during the initial 2 years of SV lens wear, but  
348 only by 0.35mm in the following 5 years of OK lens wear (Table 4).

349

350

## 351 DISCUSSION

352 This study assessed the long-term efficacy of OK lens wear in reducing the rate  
353 of axial elongation over a period of as long as 7 years in White European  
354 subjects. The significant reduction in manifest myopia and the rate of myopia  
355 progression found in the OK group after initial lens wear remained throughout  
356 the 7-year period and is primarily attributed to the corneal reshaping effect  
357 induced by OK contact lens wear and the resultant change in corneal power  
358 and shape (Table 2). The CT group, however, showed an average increase in  
359 myopia of 2.84D accompanied by negligible changes in corneal power and  
360 shape (Table 2).

361

362 Of interest is the finding of a trend towards a reduction in the rate of axial  
363 elongation of the order of 33% in the OK group in comparison to the CT group  
364 following 7-years of lens wear (Figure 2 and Table 2). Interestingly, a study  
365 estimated that reducing the rate of myopia progression by 33% would lead to a  
366 reduction of 73% in the frequency of high myopia ( $<-5.00D$ );<sup>29</sup> such reduction  
367 could therefore have important implications in terms of reducing ocular-related  
368 morbidity<sup>7</sup> and healthcare costs.<sup>8, 9</sup>

369

370 Despite differences in corneal topography and contact lens-induced responses  
371 between Caucasian and Japanese ethnicities have been previously reported,<sup>30,</sup>  
372 <sup>31</sup> our results are similar to those reported by Hiraoka et al.<sup>23</sup> We found OK to  
373 reduce the rate of axial elongation by 33% after 7 years of lens wear, whereas  
374 Hiraoka et al. found OK to reduce the rate of axial elongation by 31% after 5  
375 years of lens wear.<sup>23</sup> The study of Hiraoka et al. was performed in Japanese  
376 subjects using one particular OK contact lens design (i.e.  $\alpha$ Ortho-K; Alpha  
377 Corp., Nagoya, Japan),<sup>23</sup> whereas the present study was undertaken in White  
378 European subjects using a different OK lens design (i.e. Menicon Z Night,  
379 Menicon Co., Ltd, Nagoya, Japan). Interestingly, our results also agree with  
380 those of Hiraoka et al. in that the benefit of OK in reducing the axial elongation  
381 of eye diminishes with longer periods of lens wear.

382

383 The reduced efficacy of myopia control with long periods of lens wear found in  
384 this study may be attributed to the natural history of myopia progression, in

385 which there is a reduced rate of axial elongation with increased age, thereby  
386 making it more difficult to find significant differences between groups in axial  
387 length over longer periods of lens wear (Figures 2 and 3, and Table 2). In fact,  
388 the increases in axial length over the first 24 months of this study were  
389 remarkably similar to those found between 24 and 84 months for both the OK  
390 ( $0.42\pm 0.05$  and  $0.39\pm 0.04$ mm, respectively) and the CT ( $0.71\pm 0.10$  and  
391  $0.65\pm 0.11$ mm, respectively) groups, clearly indicating a decrease in the rate of  
392 axial elongation regardless of the visual correction being worn (Figure 3 and  
393 Table 2). It is well established that older age is associated with smaller  
394 increases in myopia and axial elongation. Furthermore, it has been previously  
395 reported that myopia stabilizes at around 16 years of age.<sup>32</sup> Subjects in this  
396 study had mean ages of 10 and 12 years at baseline and following 2 years of  
397 OK lens wear, respectively. Therefore, a reduced rate of myopia progression  
398 would be expected on these subjects during the subsequent 5 years of data  
399 collection.

400

401 Greater corneal power was found to be associated with smaller axial elongation  
402 in OK wearers (Figure 4). Following OK lens wear, a steeper cornea is likely to  
403 provide a smaller treatment zone of central corneal flattening<sup>33</sup> and a wider  
404 peripheral ring of increased corneal power. Therefore, it is feasible that a  
405 steeper cornea facilitates corneal reshaping and reduction in axial elongation  
406 following OK lens wear.<sup>12, 26</sup>

407

408 The large variability in the increases in axial length found in the 8 subjects who  
409 discontinued OK lens wear at 2-years and switched to SCL wear could be  
410 attributed to the length of time that SCLs were worn after ceasing OK lens wear  
411 (Figure 5), individual differences and differences in the power profile between  
412 the different SCLs worn (Figure 6).<sup>34</sup> In any event, the results found on the  
413 effect of switching treatments appear to be consistent with those found in the  
414 OK and CT groups over the 7-year period in that the efficacy of OK diminishes  
415 and resumes with discontinuation and restoration of OK lens wear, respectively.

416

417 A limitation of this study is the potential bias introduced by subjects' self-  
418 selection to continue wearing OK, SV or SCL. However, the major limitation

419 concerns the relatively small sample size employed in this study. The overall  
420 power to detect between-subjects differences (i.e. OK vs. CT) in the general  
421 linear model employed in our study was  $P=0.68$  (*IBM SPSS Statistics*).  
422 However, the power varied at each of the different time points, being lowest at  
423 the 6- ( $P=0.16$ ) and 84-month visits ( $P=0.47$ ) and highest at the 12- ( $P=0.81$ ), 18-  
424 ( $P=0.76$ ) and 24-month visits ( $P=0.73$ ), indicating that the relatively low  
425 statistical power found at the 84-month visit is not only related to the sample  
426 size employed but also to the large variability in changes in axial length in both  
427 the OK ( $0.91 \pm 0.63$  mm) and CT ( $1.36 \pm 0.63$  mm) groups. Taking the standard  
428 deviation of the change in axial length (0.63) and the difference in axial length  
429 found between groups at the 84-month visit (0.45 mm), a sample size of 32  
430 subjects per group would be needed for a designated statistical power of 0.80  
431 at  $\alpha = 0.05$ . Despite the above-mentioned limitations, our study offers  
432 notable features such as being the first study to assess the efficacy of OK lens  
433 wear in White European subjects in reducing the rate of axial elongation over a  
434 period of as long as 7 years. In addition, the study measures changes in axial  
435 elongation over the entire follow-up period with the *IOLMaster*, a partial  
436 coherence interferometer well known to provide excellent resolution and  
437 repeatability.<sup>28</sup> Nonetheless, randomized, controlled, clinical trials are warranted  
438 to confirm the findings of this study.

439

440 In summary, a trend towards a reduction in the rate of axial elongation of the  
441 order of 33% was found with long-term OK lens wear in comparison to SV and  
442 SCL wearers over a period of 7 years. The reduction observed over time in the  
443 efficacy of OK lens wear in slowing the axial elongation of the eye might be  
444 partly attributed to axial length (and myopia) stabilization as children approach  
445 the teenage years.<sup>32</sup> Reducing myopia progression has important implications  
446 in terms of reducing ocular-related morbidity<sup>7</sup> and healthcare costs.<sup>8,9</sup>

447

448

449

450

451

**452 DECLARATION OF INTEREST**

453 The study has been supported in part by Menicon Co., Ltd by providing  
454 spectacles or contact lenses and contact lens solutions and by Novovision  
455 Ophthalmology Clinic by providing ocular examinations and contact lens fittings  
456 and aftercares free of charge to all subjects throughout the study. Jacinto  
457 Santodomingo-Rubido and Keiji Sugimoto are full-time employees of Menicon  
458 Co., Ltd. The authors alone are responsible for the content and writing of the  
459 paper.

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495 **REFERENCES**

496

497 1. Dandona R, Dandona L. Refractive error blindness. Bull World Health  
498 Organ 2001;79:237–43

499

500 2. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et  
501 al. Global prevalence of myopia and high myopia and temporal trends  
502 from 2000 through 2050. Ophthalmology 2016; 123:1036-42.

503

504 3. Gilmartin B. Myopia: precedents for research in the twenty first century.  
505 Clin Exp Ophthalmol 2004;32:305–24.

506

507 4. Vongphanit J, Mitchell P, Wang JJ. Prevalence and progression of  
508 myopic retinopathy in an older population. Ophthalmology  
509 2002;109:704–11.

510

511 5. Wong TY, Klein BEK, Klein R, Knudtson M, Lee KE. Refractive errors,  
512 intraocular pressure and glaucoma in a white population. Ophthalmology  
513 2003;110:211–7.

514

515 6. Saw S-M, Gazzard G, Shih-Yen EC, Chua WH. Myopia and associated  
516 pathological conditions. Ophthal Physiol Opt 2005;25:381–91.

517

518 7. Flitcroft DI. The complex interactions of retinal, optical and environmental  
519 factors in myopia aetiology. Prog Ret Eye Res 2012;31:622–60.

520

521 8. Vitale S, Cotch MF, Sperduto R, Ellwein L. Costs of refractive correction  
522 of distance vision impairment in the United States, 1999–2002.  
523 Ophthalmology 2006;113:2163–70.

524

525 9. Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N, et al. The  
526 economic burden of major adult visual disorders in the United States.  
527 Arch Ophthalmol. 2006;124:1754-1760.

528

529 10. Saw SM, Shin-Yen EC, Koh A, Tan D. Interventions to retard myopia  
530 progression in children. Ophthalmology 2002;109:415-427.

531

532 11. Walline JJ, Lindsley K, Vedula SS, Cotter SA, Mutti DO, Twelker JD.  
533 Interventions to slow progression of myopia in children. Cochrane  
534 Database Syst Rev 2011;12:CD004916.

535

536 12. Smith EL. Optical treatment strategies to slow myopia progression:  
537 effects of the visual extent of the optical treatment zone. Exp Eye Res  
538 2013;114:77-88.

539

540 13. Cho P, Cheung SW, Edwards M. The longitudinal orthokeratology  
541 research in children (LORIC) in Hong Kong: a pilot study on refractive  
542 changes and myopic control. Curr Eye Res 2005;30:71-80.

543

- 544 14. Walline JJ, Jones LA, Sinnott LT. Corneal reshaping and myopia  
545 progression. *Br J Ophthalmol* 2009;93:1181–5.  
546
- 547 15. Kakita T, Hiraoka T, Oshika T. Influence of overnight orthokeratology on  
548 axial length elongation in childhood myopia. *Invest Ophthalmol Vis Sci*  
549 2011;52:2170-4.  
550
- 551 16. Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-term  
552 effect of overnight orthokeratology on axial length elongation in childhood  
553 myopia: a 5-year follow-up study. *Invest Ophthalmol Vis Sci*  
554 2012;53:3913-9.  
555
- 556 17. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R.  
557 Myopia control with orthokeratology contact lenses in Spain: refractive  
558 and biometric changes. *Invest Ophthalmol Vis Sci* 2012;53:5060-5.  
559
- 560 18. Cho P, Cheung SW. Retardation of Myopia in Orthokeratology (ROMIO)  
561 Study: a 2-year randomized clinical trial. *Invest Ophthalmol Vis Sci*  
562 2012;53:7077-85.  
563
- 564 19. Wen D, Huang J, Chen H, Bao F, Savini G, Calossi A, et al. Efficacy and  
565 acceptability of orthokeratology for slowing myopic progression in  
566 children: a systematic review and meta-analysis. *J Ophthalmol*  
567 2015;2015:360806.  
568
- 569 20. Kwok-Hei Mok A, Sin-Ting Chung C. Seven-year retrospective analysis  
570 of the myopic control effect of orthokeratology in children: a pilot study.  
571 *Clinical Optometry* 2011;3:1-4.  
572
- 573 21. Downie LE, Lowe R. Corneal reshaping influences myopic prescription  
574 stability (CRIMPS): an analysis of the effect of orthokeratology on  
575 childhood myopic refractive stability. *Eye Contact Lens* 2013;39:303-10.  
576
- 577 22. Cheung SW, Cho P. Validity of axial length measurements for monitoring  
578 myopic progression in orthokeratology. *Invest Ophthalmol Vis Sci*  
579 2013;54:1613-5.  
580
- 581 23. Hiraoka T, Kakita T, Okamoto F, Takahashi H, Oshika T. Long-term  
582 effect of overnight orthokeratology on axial length elongation in childhood  
583 myopia: a 5-year follow-up study. *Invest Ophthalmol Vis Sci*  
584 2012;53:3913-9.  
585
- 586 24. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R.  
587 Myopia control with orthokeratology contact lenses in Spain (MCOS):  
588 study design and general baseline characteristics. *J Optom* 2009;2:215-  
589 22.  
590
- 591 25. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R.  
592 Orthokeratology vs. spectacles: adverse events and discontinuations.  
593 *Optom Vis Sci* 2012;89:1133-9.

- 594 26. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R.  
595 Factors preventing myopia progression with orthokeratology correction.  
596 *Optom Vis Sci* 2013;90:1225-36.  
597
- 598 27. Santodomingo-Rubido J, Villa-Collar C, Gilmartin B, Gutiérrez-Ortega R.  
599 Short-term changes in ocular biometry and refraction after  
600 discontinuation of long-term orthokeratology. *Eye Contact Lens*  
601 2014;40:84-90.  
602
- 603 28. Santodomingo-Rubido J, Mallen EA, Gilmartin B, Wolffsohn JS. A new  
604 non-contact optical device for ocular biometry. *Br J Ophthalmol*  
605 2002;86:458-2.  
606
- 607 29. Brennan, NA. Predicted reduction in high myopia for various degrees of  
608 myopia control. *Contact Lens Anterior Eye* 2012;35:e14-e15.  
609
- 610 30. Hickson-Curran S, Brennan NA, Igarashi Y, Young G. Comparative  
611 evaluation of Asian and White ocular topography. *Optom Vis Sci*  
612 2014;91:1396-405.  
613
- 614 31. Hamano H, Jacob JT, Senft CJ, Hamano T, Hamano T, Mitsunaga S, et  
615 al. Differences in contact lens induced responses in the corneas of Asian  
616 and non-Asian subjects. *CLAO J.* 2002;28:101–4.  
617
- 618 32. Dong LM, Fazzari M, Gwiazda J, Hyman L, Norton T, Thorn F, et al.  
619 Myopia stabilization and associated factors among participants in the  
620 correction of myopia evaluation trial (COMET). *Invest Ophthalmol Vis Sci*  
621 2013;54:7871-84.  
622
- 623 33. Munneryn, CR, Koons, SJ, Marshall, J. Photorefractive keratectomy: a  
624 technique for laser refractive surgery. *J Refract Surg* 1988;14:46-52.  
625
- 626 34. Wagner S, Conrad F, Bakaraju RC, Fedtke C, Ehrmann K, Holden BA.  
627 Power profiles of single vision and multifocal soft contact lenses. *Cont*  
628 *Lens Anterior Eye* 2015;38:2-14.  
629  
630

631 **FIGURE LEGENDS**

632

633 **Figure 1.** Flow-chart of the subjects recruited for the study. SV, distance single-  
634 vision spectacles, SCL, soft contact lenses.

635

636 **Figure 2.** Changes (mean  $\pm$  SD) in axial length (mm) from baseline over time  
637 for the OK (black, solid circles) and CT (white, open circles) groups. Error bars  
638 represent one standard error of the mean. Asterisks indicate statistically  
639 significant differences in the change in axial length between groups at 12-, 18-  
640 and 24-months time intervals (all  $p \leq 0.02$ ). OK, orthokeratology; CT, control

641

642 **Figure 3.** Simple linear regressions between the change in axial length at 7  
643 years relative to baseline and age at baseline for the orthokeratology (black,  
644 solid circles and solid line) and control groups (white, open circles and dashed  
645 line).

646

647 **Figure 4.** Simple linear regressions between the change in axial length at 7  
648 years relative to baseline and mean central corneal power at baseline for the  
649 orthokeratology (black, solid circles and solid line) and control groups (white,  
650 open circles and dashed line).

651

652 **Figure 5.** Simple linear regressions between the change in axial length at 84-  
653 compared with 24-months and the duration of soft contact lens wear.

654

655 **Figure 6.** Changes in axial length (mm) from baseline over time for eight  
656 subjects who switched from OK to SCL after an initial phase of 2 years of OK  
657 lens wear. OK, orthokeratology; SCL, soft contact lens.

658

659

660

661

662

663

664

665 **TABLE LEGENDS**

666

667 **Table 1.** Baseline demographics, refractive and biometric data for both  
668 treatment groups. Variables are expressed as mean  $\pm$  1SEM. OK,  
669 orthokeratology; CT, control.

670

671 **Table 2.** Mean ( $\pm$  SEM) refractive and biometric values for the OK and CT  
672 groups who completed the 7-years study at each time interval. OK,  
673 orthokeratology; CT, control.

674

675 **Table 3.** Simple linear regressions between the change in axial length at 7-  
676 years relative to baseline and the different baseline variables for both the OK  
677 and CT groups. The strength of association between the different factors is  
678 summarized using linear regression equations,  $R^2$  values and p-values. OK,  
679 orthokeratology; CT, control; MSE, mean spherical equivalent.

680

681 **Table 4.** Mean ( $\pm$  SEM) refractive and biometric values for the 8 subjects who  
682 switched from OK to SCL as well as for one single subject who switched from  
683 SV to OK at each time interval. OK, orthokeratology; SCL, soft contact lens; SV,  
684 single-vision spectacles.

685

686

687

688

689

690

691

692

693

694

695

696

697

|                                       | <b>Orthokeratology</b> | <b>Control</b> | <b>p-value</b> |
|---------------------------------------|------------------------|----------------|----------------|
| <b>Age (years)</b>                    | 10.4 ± 0.5             | 9.6 ± 0.4      | 0.244          |
| <b>Male/female ratio</b>              | 8/6                    | 7/9            | 1.00           |
| <b>Sphere (D)</b>                     | -2.27 ± 0.31           | -2.16 ± 0.26   | 0.375          |
| <b>Cylinder (mm)</b>                  | -0.25 ± 0.09           | -0.30 ± 0.09   | 0.876          |
| <b>Axial length (mm)</b>              | 24.39 ± 0.23           | 24.08 ± 0.27   | 0.621          |
| <b>Flatter meridian (D)</b>           | 43.18 ± 0.45           | 43.45 ± 0.46   | 0.665          |
| <b>Steeper meridian (D)</b>           | 43.82 ± 0.41           | 44.11 ± 0.54   | 0.667          |
| <b>Corneal shape factor (p-value)</b> | 0.70 ± 0.03            | 0.70 ± 0.02    | 0.982          |

**Table 1.** Baseline demographics, refractive and biometric data for both treatment groups. Variables are expressed as mean ± SEM

|                                    | Baseline     | 6-months     | 12-months    | 18-months    | 24-months    | 84-months    |
|------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| <b>Refractive components</b>       |              |              |              |              |              |              |
| Sphere (D)                         |              |              |              |              |              |              |
| Orthokeratology                    | -2.27 ± 0.31 | -0.14 ± 0.07 | -0.21 ± 0.07 | -0.14 ± 0.07 | -0.23 ± 0.06 | -0.29 ± 0.10 |
| Control                            | -2.16 ± 0.26 | -2.39 ± 0.29 | -2.74 ± 0.30 | -3.07 ± 0.30 | -3.37 ± 0.32 | -5.00 ± 0.43 |
| Cylinder (D)                       |              |              |              |              |              |              |
| Orthokeratology                    | -0.25 ± 0.09 | -0.38 ± 0.09 | -0.27 ± 0.10 | -0.30 ± 0.10 | -0.29 ± 0.13 | -0.30 ± 0.10 |
| Control                            | -0.30 ± 0.09 | -0.25 ± 0.08 | -0.30 ± 0.08 | -0.30 ± 0.11 | -0.37 ± 0.10 | -0.59 ± 0.10 |
| <b>Biometric components</b>        |              |              |              |              |              |              |
| Axial length (mm)                  |              |              |              |              |              |              |
| Orthokeratology                    | 24.39 ± 0.23 | 24.52 ± 0.23 | 24.41 ± 0.23 | 24.71 ± 0.24 | 24.81 ± 0.25 | 25.30 ± 0.31 |
| Control                            | 24.08 ± 0.27 | 24.25 ± 0.27 | 24.46 ± 0.27 | 24.61 ± 0.26 | 24.78 ± 0.26 | 25.43 ± 0.27 |
| Flatter corneal meridian power (D) |              |              |              |              |              |              |
| Orthokeratology                    | 43.18 ± 0.45 | 41.32 ± 0.46 | 41.36 ± 0.48 | 41.10 ± 0.44 | 41.36 ± 0.49 | 40.49 ± 0.41 |
| Control                            | 43.45 ± 0.46 | 43.51 ± 0.46 | 43.52 ± 0.46 | 43.45 ± 0.45 | 43.47 ± 0.48 | 42.69 ± 0.42 |
| Steeper corneal meridian power (D) |              |              |              |              |              |              |
| Orthokeratology                    | 43.82 ± 0.41 | 42.23 ± 0.47 | 42.12 ± 0.48 | 41.99 ± 0.43 | 42.16 ± 0.47 | 41.35 ± 0.41 |
| Control                            | 44.11 ± 0.54 | 44.29 ± 0.51 | 43.36 ± 0.51 | 44.31 ± 0.52 | 44.18 ± 0.53 | 43.68 ± 0.45 |
| Corneal shape factor (p-value)     |              |              |              |              |              |              |
| Orthokeratology                    | 0.70 ± 0.03  | 0.82 ± 0.05  | 0.79 ± 0.04  | 0.82 ± 0.04  | 0.76 ± 0.05  | 0.78 ± 0.05  |
| Control                            | 0.70 ± 0.02  | 0.70 ± 0.02  | 0.73 ± 0.02  | 0.71 ± 0.02  | 0.74 ± 0.02  | 0.69 ± 0.03  |

**Table 2.** Mean (± SEM) refractive and biometric values for the OK and CT groups who completed the 7-years study at each time interval.

|                                       | <b>Orthokeratology</b>   | <b>Control</b>  | <b>Statistical differences between groups in the slopes of the regression lines (p-value)</b> |
|---------------------------------------|--|---|---|
| <b>Age (years)</b>                    | y=-0.165x + 2.620<br>R <sup>2</sup> =0.142, p=0.101              | <b>y=-0.220x + 3.469</b><br><b>R<sup>2</sup>=0.274, p=0.022</b> | p=0.208   |
| <b>MSE refractive error (D)</b>       | y=0.070x + 1.073<br>R <sup>2</sup> =0.000, p=0.669               | y=-0.075x + 1.528<br>R <sup>2</sup> =0.000, p=0.653             | p=0.987   |
| <b>Axial length (mm)</b>              | y=0.115x - 1.904<br>R <sup>2</sup> =0.000, p=0.591               | y=-0.206x + 6.315<br>R <sup>2</sup> =0.048, p=0.207             | p=0.085   |
| <b>Mean central keratometry (D)</b>   | <b>y=-0.235x + 11.131</b><br><b>R<sup>2</sup>=0.290, p=0.027</b> | y=-0.021x + 2.282<br>R <sup>2</sup> =0.000, p=0.817             | p=0.044   |
| <b>Corneal shape factor (p-value)</b> | y=-1.541x + 1.982<br>R <sup>2</sup> =0.000, p=0.376              | y=-1.868x + 2.659<br>R <sup>2</sup> =0.005, p=0.319             | p=0.058   |

**Table 3.** Simple linear regressions between the change in axial length at 7-years relative to baseline and the different baseline variables for both the OK and CT groups. The strength of association between the different factors is summarized using linear regression equations, R<sup>2</sup> values and p-values. OK, orthokeratology; CT, control; MSE, mean spherical equivalent

|                                    | Baseline     | 6-months     | 12-months    | 18-months    | 24-months    | 84-months    |
|------------------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| <b>Refractive components</b>       |              |              |              |              |              |              |
| Sphere (D)                         |              |              |              |              |              |              |
| OK to SCL                          | -2.31 ± 0.38 | -0.31 ± 0.06 | -0.25 ± 0.13 | -0.33 ± 0.08 | -0.50 ± 0.12 | -4.81 ± 0.62 |
| SV to OK                           | -3.75        | -4.00        | -4.00        | -4.50        | -5.00        | -0.25        |
| Cylinder (D)                       |              |              |              |              |              |              |
| OK to SCL                          | -0.38 ± 0.08 | -0.22 ± 0.07 | -0.44 ± 0.11 | -0.31 ± 0.09 | -0.19 ± 0.09 | -0.59 ± 0.16 |
| SV to OK                           | -0.75        | -0.75        | -0.75        | -0.75        | -0.50        | -0.75        |
| <b>Biometric components</b>        |              |              |              |              |              |              |
| Axial length (mm)                  |              |              |              |              |              |              |
| OK to SCL                          | 24.66 ± 0.30 | 24.75 ± 0.30 | 24.90 ± 0.32 | 25.06 ± 0.32 | 25.23 ± 0.32 | 26.03 ± 0.41 |
| SV to OK                           | 25.00        | 25.39        | 25.39        | 25.72        | 25.81        | 26.16        |
| Flatter corneal meridian power (D) |              |              |              |              |              |              |
| OK to SCL                          | 42.51 ± 0.75 | 40.74 ± 0.67 | 40.84 ± 0.62 | 40.71 ± 0.74 | 40.82 ± 0.82 | 41.54 ± 0.74 |
| SV to OK                           | 43.30        | 43.20        | 43.20        | 43.44        | 43.44        | 40.40        |
| Steeper corneal meridian power (D) |              |              |              |              |              |              |
| OK to SCL                          | 43.24 ± 0.63 | 41.68 ± 0.70 | 41.69 ± 0.61 | 41.78 ± 0.77 | 41.76 ± 0.79 | 42.57 ± 0.67 |
| SV to OK                           | 44.00        | 43.90        | 43.90        | 43.95        | 44.12        | 41.5         |
| Corneal shape factor (p-value)     |              |              |              |              |              |              |
| OK to SCL                          | 0.65 ± 0.04  | 0.87 ± 0.05  | 0.94 ± 0.02  | 0.85 ± 0.05  | 0.91 ± 0.04  | 0.68 ± 0.03  |
| SV to OK                           | 0.80         | 0.82         | 0.85         | 0.86         | 0.85         | 0.94         |

**Table 4.** Mean (± SEM) refractive and biometric values for the 8 subjects who switched from OK to SCL as well as for one single subject who switched from SV to OK at each time interval. OK, orthokeratology; SCL, soft contact lens; SV, single-vision spectacles











